
Empasug 25mg
MRP: 1,050
Packaging: 10X10
Pack Type: tablet
Composition:
Empagliflozin 25 mg IR
Indication:
Type 2 diabetes mellitus (T2DM) to improve blood sugar control, Heart failure to reduce cardiovascular death and hospitalization, Chronic kidney disease (CKD) to slow progression and lower CV risk.
Description:
Empagliflozin 25mg IR is a once-daily oral antidiabetic drug from the SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor class, used in the management of type 2 diabetes mellitus. It works by blocking glucose reabsorption in the kidneys, thereby promoting glucose excretion in the urine. This mechanism helps lower blood sugar levels independently of insulin.
The 25mg strength is often prescribed for patients requiring intensified glycemic control or those who do not achieve adequate control on the 10mg dose. In addition to its glucose-lowering effects, Empagliflozin 25mg has demonstrated cardiovascular and renal protective benefits, including reduced risk of hospitalization due to heart failure and progression of kidney disease.
This immediate-release (IR) formulation ensures rapid absorption and is suitable for daily use with or without food.
Tags:
- Enhances urinary glucose excretion to reduce blood sugar
- Provides cardiovascular protection in diabetics with heart risks
- Helps slow kidney disease progression
- Supports weight loss and blood pressure control
- Convenient once-daily oral dose with no need for insulin
Usage Information
Dosage
Typical Dose: 25mg once daily, preferably in the morning. May be started at 10mg and titrated to 25mg based on clinical response. Can be taken with or without meals. Ensure adequate fluid intake during treatment.
Side Effects
Common side effects: Frequent urination Genital or urinary tract infections Thirst, dry mouth Weight loss Serious side effects (rare): Euglycemic diabetic ketoacidosis Hypotension (especially in elderly or dehydrated patients) Acute kidney injury Fournier’s gangrene (rare soft tissue infection)
Contraindications
Type 1 diabetes Diabetic ketoacidosis (DKA) Severe renal impairment (eGFR < 30 mL/min/1.73m²) Hypersensitivity to Empagliflozin Dehydrated or volume-depleted patients Recurrent urinary or genital infections
Availability
Empagliflozin 25mg tablet Empagliflozin IR dosage SGLT2 inhibitor for diabetes Empagliflozin benefits and side effects Type 2 diabetes oral medication Empagliflozin 25mg for heart and kidney protection High dose empagliflozin tablets Blood sugar control SGLT2 medicine
